Home/Pipeline/DFTX-101

DFTX-101

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Definium Therapeutics

About Definium Therapeutics

Definium Therapeutics is a public biotech company dedicated to translating innovative science into transformative medicines for patients with cancer and immune disorders. Its core strategy involves targeting key disease-driving pathways that have eluded conventional drug discovery approaches. The company's lead asset is in Phase 1/2 development, supported by a robust preclinical pipeline and a strong intellectual property portfolio. Definium aims to establish itself as a leader in precision oncology and immunology through strategic clinical execution and potential partnerships.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
SHR-1701	Jiangsu Hengrui Medicine	Phase 1	Active
BAY 1895344	Bayer	Phase 1	Active
HS-10342	Hansoh Pharma	Phase 1/2	Active
ANKTIVA® + M-ceNK	ImmunityBio	Phase 1	Active
REC-617	Recursion Pharmaceuticals	Phase 1/2	Active
ZW220	Zymeworks	Preclinical	Active
NX-1607	Nurix Therapeutics	Phase 1a	Active
IMA402 (TCR Bispecific)	Immatics	Phase 1	Active
IMA403 (TCR Bispecific)	Immatics	Pre-clinical	Research
BCA101	Bicara Therapeutics	Phase 1	Completed
AN4005	Adlai Nortye	Preclinical	IND-enabling
AN3025	Adlai Nortye	Preclinical	Active